Eledon Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Eledon Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($17.46M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($11.22M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($11.22M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.50M) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($6.50M) | Aug 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($6.50M) | Nov 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | $76.97M | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($44.91M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($44.91M) | Aug 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($23.63M) | Aug 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($23.63M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($23.63M) | Aug 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.91M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($65.76M) | Aug 19, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($65.76M) | Nov 12, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($10.77M) | Aug 19, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($10.77M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($10.77M) | Aug 19, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.47M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.25M) | Aug 10, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($19.07M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($24.73M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($17.96M) | Aug 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($20.51M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($14.50M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($10.87M) | Aug 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.20M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.35M) | Aug 19, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.11M) | Aug 19, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.60M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($9.28M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($9.86M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($10.51M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($7.97M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($9.01M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($6.15M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.59M) | Aug 12, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($3.38M) | May 14, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($2.92M) | Nov 16, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($4.09M) | Aug 14, 2020 |